Tag - Corbus Pharmaceuticals

Corbus Pharmaceuticals Appoints Rachael Brake, Ph.D., as Chief Scientific Officer

Corbus Pharmaceuticals Holdings, Inc. today announced the appointment of Rachael Brake, Ph.D., as Chief Scientific Officer, furthering the Company's mission of connecting innovation to purpose. Dr. Brake will build upon Corbus' commitment to immuno-oncology and joins the Company following the recent acquisition of monoclonal antibodies that inhibit TGFβ activation. Dr. Brake formerly held leadership roles at Takeda Oncology, including Vice President, Global Project Leader in the Oncology Therapeutic Area and Head, U.S. Medical Affairs, Oncology Business Unit. Read more >>
Read more...

Corbus Pharmaceuticals Licenses Two Integrin Targeting mAbs Further Expanding Pipeline into Cancer and Fibrotic Diseases

Corbus diversifies pipeline with two new mAbs that target integrins that inhibit activation of TGFβ. High potency anti-αvβ8 mAb licensed from University of California San Francisco andanti-αvβ6/αvβ8 mAb licensed from Panorama Research Inc. Both mAbs expected to start Phase 1 testing in 2022. Capital and resources in place to advance multiple programs into clinical development. Read more >>
Read more...

Corbus Pharmaceuticals Announces Publication of Two Abstracts at EULAR 2021 Virtual Congress

Corbus Pharmaceuticals Holdings, Inc., a clinical-stage drug development company pioneering transformative medicines that target the endocannabinoid system, today announced the publication of two abstracts at the European League Against Rheumatism (EULAR) 2021 Virtual Congress that will be taking place June 2-5, 2021. Read more >>
Read more...

Corbus Pharmaceuticals Announces Presentations at the New York Academy of Sciences Webinar on Targeting the Endocannabinoid System to Treat Human Diseases

Corbus Pharmaceuticals Holdings, Inc., a clinical-stage drug development company pioneering transformative medicines that target the endocannabinoid system, today announced it will participate in the New York Academy of Sciences' webinar on January 27, 2021 on the endocannabinoid system as a target for therapeutic agents. Read more >>
Read more...

Corbus Pharmaceuticals to Present at the Jefferies Virtual London Healthcare Conference

Corbus Pharmaceuticals Holdings, Inc., a clinical-stage drug development company pioneering transformative medicines that target the endocannabinoid system, today announced that Yuval Cohen, Ph.D., Chief Executive Officer of Corbus, will participate in a fireside chat at the Jefferies Virtual London Healthcare Conference on Thursday, November 19, 2020 at 12:35 PM EST. Read more >>
Read more...

Corbus Pharmaceuticals Announces Presentation of Data from its Phase 2b Study in Cystic Fibrosis at NACFC 2020

Corbus Pharmaceuticals Holdings, Inc., a clinical-stage drug development company pioneering transformative medicines that target the endocannabinoid system, today announced the presentation of the preliminary data from its 28 week Phase 2b study of lenabasum in patients with cystic fibrosis (CF) at the North American Cystic Fibrosis Conference (NACFC) held online, Oct 7-23, 2020. Read more >>
Read more...

Corbus Pharmaceuticals Announces Three Lenabasum Abstracts to be Presented at ACR Convergence 2020

Corbus Pharmaceuticals Holdings, Inc., a clinical-stage drug development company pioneering transformative medicines that target the endocannabinoid system, today announced the presentation of three abstracts at the American College of Rheumatology (“ACR”) Convergence 2020 being held online, November 5–9, 2020. Read more >>
Read more...